The Business Council of Westchester is proud to spotlight one of our members, Regeneron Pharmaceuticals, on a truly historic milestone in medical innovation. On April 23, 2026, Regeneron announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Otarmeni™ (lunsotogene parvec-cwha) — the first and only gene therapy approved for a form of genetic hearing loss caused by mutations in the OTOF gene. This breakthrough represents a major leap forward in the treatment of severe-to-profound sensorineural hearing loss. In clinical trials, the one-time therapy demonstrated remarkable results: 80% of participants experienced significant hearing improvement within 24 weeks […]